Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net income (loss)	$ (75,711,712)	$ (31,170,223)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,195,513	4,929,289
Amortization of right-of-use assets	488,621	1,250,229
Amortization of deferred financing costs	1,716,635	1,382,651
Impairments and other losses, net	50,217,492	8,937,677
Stock-based compensation	639,334	13,817,334
Accretion of interest on acquisition liabilities	53,102	125,398
Net gain on sale of subsidiary	0	(82,894)
Imputed interest for note payable	0	10,000
Loss on early termination of operating lease	0	(202,150)
Loss on derivative liabilities	0	316,245
Provision for bad debt	(176,958)	(4,811)
Partial liquidated damages expense	227,400	3,916,350
Change in operating assets and liabilities:
Accounts receivable	(2,602,949)	(15,266,014)
Prepaid expenses	(2,001,584)	(2,802,733)
Accounts payable and accrued expenses	7,006,631	16,211,966
Other assets	(85,328)	(770,629)
Operating lease liability	(1,089,175)	(3,487,528)
Due to related parties	0	(7,000)
Deferred revenue	507,803	4,077,739
Other long-term liabilities	(204,094)	(161,900)
Net cash (used in) provided by operating activities	(14,819,269)	1,423,296
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash paid for acquisition of Converge	0	(82,730,000)
Net cash paid for sale of Mission Media UK	0	(613,535)
Purchase of property and equipment	(46,805)	(242,056)
Net cash used in investing activities	(46,805)	(83,585,591)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments made for bank loan	(1,912,500)	(1,912,500)
Proceeds from at-the-market offering, net	9,271	0
Payments for note payable to related party	(30,000)	(90,000)
Proceeds from the issuance of preferred stock, net of offering costs	0	44,405,000
Proceeds from bank loan, net of debt issuance cost	0	69,717,960
Payments made for the redemption of Series A preferred stock	0	(446,400)
Payment of stimulus loan programs	0	(435,000)
Payments made for loss contingency on equity issuance	0	(3,615,000)
Net cash (used in) provided by financing activities	(1,933,229)	107,624,060
Effect of exchange rate on cash	0	1,223,078
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(16,799,303)	26,684,843
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — beginning of period	28,403,797	5,982,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — end of period	11,604,494	32,666,843
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Income taxes	253,100	0
Interest expense	5,714,032	4,076,243
Noncash investing and financing activities:
Settlement of contingent liability in common shares	2,673,176	0
Write-off of property and equipment	291,641	0
Fair value of common stock issued relating to the Converge Acquisition	0	14,875,000
Warrants issued relating to debt financing	0	2,232,000
Warrants issued relating to equity financing	0	28,407,000
Series E Preferred Stock
Noncash investing and financing activities:
Conversion of Series E Preferred shares to common shares	31,078,000	274,237
Warrant
Noncash investing and financing activities:
Conversion of Series E Preferred shares to common shares	$ 34,690,000	$ 0